A

AOTI

Topical oxygen therapy for chronic wounds

Overview

AOTI develops wound-care technology for chronic wounds, led by a multi-modality topical wound oxygen therapy. It delivers oxygen directly to the wound site to support healing and is designed to fit into existing clinical care without disrupting practices. The approach stands out through strong clinical validation and endorsements from major medical organizations, such as ADA and IWGDF, and by focusing on easy integration into standard care. Its goal is to improve patient outcomes, reduce amputations, and expand access to high-quality wound care for all patients.

Significant Headcount Growth

Work here?Claim your company

About AOTI

Simplify's Rating
Why AOTI is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & ManufacturingHealthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Oceanside, CA

Founded

2004

Get referred to AOTI

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • H1 2026 revenue rose 10.8% to $35.3 million; underlying growth hit 18.8%.
  • Operating cash flow turned positive at $0.9 million, helped by VA revenue and working capital.
  • A November 10, 2026 China distribution pact targets nearly $18 million minimum sales.

What critics are saying

  • Arizona Medicaid halted new patients in April 2026, leaving an $18.7 million receivable.
  • Veterans Affairs supplied 57% of H1 2026 revenue, creating concentration risk if procurement slows.
  • CMS final LCD ends July 2027; an adverse decision would cap TWO2 reimbursement and growth.

What makes AOTI unique

  • AOTI's TWO2 therapy has CMS proposed LCD coverage for diabetic foot ulcers since July 24, 2026.
  • The company pairs home-applied oxygen therapy with remote monitoring and wound imaging.
  • NEXA NPWT extends AOTI beyond oxygen therapy into disposable home-care wound management.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$25.7M

Above

Industry Average

Funded Over

1 Rounds

IPO funding comparison data is currently unavailable. We're working to provide this information soon!
IPO Funding Comparison Coming Soon

Benefits

  • 401(k) Company Match
  • Life Insurance
  • Disability Insurance
  • Paid Holidays
  • Paid Vacation
  • Paid Sick Leave
  • Employee Referral Bonus
  • Employee Discounts
  • Remote Work Options
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

0%

1 year growth

13%

2 year growth

13%
Yahoo Finance
Apr 6th, 2026
AOTI books $2.67M profit but burns through $6.6M in cash, raising questions about earnings quality

AOTI reported strong earnings that lifted its share price, but underlying cash flow metrics suggest caution. For the year to December 2025, the company posted a profit of $2.67 million but burnt through $6.6 million in free cash flow, resulting in an accrual ratio of 0.43. The high accrual ratio indicates the company's profit significantly exceeds its free cash flow, which research suggests may signal weaker future profitability. AOTI generated no free cash flow during the period and also recorded negative cash flow in the previous year. Whilst the company improved from a prior-year loss to profitability, the disconnect between reported earnings and cash generation raises questions about the sustainability of its earnings power.

Yahoo Finance
Feb 23rd, 2026
Caledonia Mining secures $150M facility as AOTI reports $66M revenue and Helix becomes Montana's first helium producer

Helix Exploration has become Montana's first helium producer, with operations scaling up at its Rudyard project as the company enters distributor discussions. Atlantic Lithium has rejected takeover talks, stating the offer undervalued its flagship Ewoyaa Lithium Project in Ghana. The board will focus on its own growth strategy instead. AOTI Inc reported a 14% increase in 2025 annual revenue to over $66 million and is awaiting a potentially transformational US reimbursement decision for its medical technology. Caledonia Mining has appointed Stanbic Bank Zimbabwe and CBZ Bank as lead banks for a new $150 million funding facility. The capital will support development of its Bilboes gold project in Zimbabwe.

Rapid Medtech Communications Ltd.
Jul 30th, 2024
AOTI announces FDA clearance of NEXATM NPWT system for use in home care setting

AOTI recently raised net proceeds of 13.5 million GBP (17.5 million USD) through an initial public offering ("IPO") on the AIM market on 18 June 2024.

MarketWatch
Jun 18th, 2024
AOTI Raises $24.8 Mln in London IPO

By Ian Walker U.S. medical-technology company AOTI raised 19.5 million pounds ($24.8 million) in its initial public offering and started trading on London's...

NewsnReleases
Jun 18th, 2024
AOTI Inc. commences trading on London Stock Exchange - NewsnReleases

AOTI has all of the building blocks in place to secure expanded market access and commercialisation of our TWO2 Therapy and to continue the staged roll-out of the NEXA NPWT System

Recently Posted Jobs

Sign up to get curated job recommendations

AOTI is Hiring for 9 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs